Kymera Therapeutics Inc (KYMR)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current KYMR market cap is 2.71B. The company's latest EPS is USD -2.2691 and P/E is -18.59.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 4.73M | 47.89M | 10.29M | 25.65M | 3.74M |
| Operating Income | -57.51M | -19.31M | -52.91M | -50.93M | -72.12M |
| Net Income | -52.87M | -14.37M | -48.56M | -42.06M | -62.49M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 2.93M | 34.03M | 72.83M | 46.83M | 78.59M |
| Operating Income | -42.21M | -46.3M | -100.53M | -161.26M | -165.53M |
| Net Income | -41.25M | -54.64M | -100.22M | -154.81M | -146.96M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 552.38M | 575.76M | 868.25M | 826.02M | 1.03B |
| Total Liabilities | 156.84M | 180.79M | 157.05M | 141.1M | 141.91M |
| Total Equity | 395.54M | 394.97M | 711.2M | 684.92M | 892.93M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 116.7M | 487.18M | 605.91M | 603.13M | 575.76M |
| Total Liabilities | 82.03M | 203.29M | 146.27M | 112.98M | 180.79M |
| Total Equity | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -110.87M | -102.83M | -39.59M | -82.53M | -132.72M |
| Investing | 120.93M | 139.89M | -330.61M | -314.97M | -472.65M |
| Financing | 2.26M | 4.19M | 353.76M | 355.17M | 606.09M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 17.91M | 88.13M | -128.95M | -153.09M | -102.83M |
| Investing | -16.49M | -422.59M | -99.84M | 20.52M | 139.89M |
| Financing | 34.91M | 289.26M | 250.28M | 153M | 4.19M |
| Market Cap | 2.71B |
| Price to Earnings Ratio | -18.59 |
| Price to Sales Ratio | 34.76 |
| Price to Cash Ratio | 24.84 |
| Price to Book Ratio | 6.92 |
| Dividend Yield | - |
| Shares Outstanding | 64.77M |
| Average Volume (1 week) | 547.74k |
| Average Volume (1 Month) | 540.09k |
| 52 Week Change | 34.68% |
| 52 Week High | 53.27 |
| 52 Week Low | 29.33 |
| Spread (Intraday) | 0.13 (0.31%) |
| Company Name | Kymera Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.kymeratx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
